Catalent's Brazilian acquisition supports global softgel strategy

By Dan Stanton

- Last updated on GMT

Related tags: China, Softgel

Catalent purchases Brazilian softgel firm Relthy Labs
Catalent purchases Brazilian softgel firm Relthy Labs
Catalent has continued its softgel expansion in emerging markets with the acquisition of Relthy Laboratórios in Brazil.

Earlier this year, Catalent Pharma Solutions boosted its drug delivery business by acquiring the Chinese softgel producer Zhejiang Jiang Yuan Tang Biotechnolgy Company​. Yesterday the firm announced it is expanding its South American operations, purchasing 100% of the shares of Indaiatuba, Brazil-based Relthy.

“South America is an important region for Catalent strategically, where we have a long established presence with softgel facilities in Argentina [Buenos Aires] and Brazil [Sorocaba] supplying domestic customers,”​ Elliott Berger, VP Global Marketing & Strategy at Catalent, told this publication.

“Continued growth in the consumer health segment, particularly in Brazil, makes the region an important one for Catalent and has led to this acquisition, significantly increasing our capabilities to better serve local customers and consumers.”

Relthy’s workforce of 350 produces approximately two billion capsules annually for prescription and over-the-counter drugs, as well as Vitamin, Mineral and Supplement (VMS) products - a new market area for Catalent to enter into.

China, Brazil and Emerging Markets

The acquisitio - of which financial details have not been divulged - adds an eleventh softgel facility to Catalent’s worldwide network and comes just two months after the firm received regulatory approval​ for the Chinese purchase.

On top of the softgel facility, Catalent “invested in a brand new facility for clinical trial supplies, developing an empty warehouse into the first full service clinical supply operation by a global company in China,”​ according to Berger.

“Emerging markets represent a growing and increasingly important segment for Catalent,”​ Berger said, adding the challenge lies in providing the same quality and supply in these regions as Catalent does in its more established markets.

He said: “This strategy led us to carefully select softgel manufacturing facilities in China and Brazil and we intend to spend significant resources in the next few years to expand their capabilities, standards and regulatory approval footprint.”

Related news

Show more

Related products

show more

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us


View more